A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study to Evaluate the Safety and Efficacy of Recombinant Human Soluble Thrombomodulin, ART-123, in Patients With Sepsis and Suspected Disseminated Intravascular Coagulation*

Jean‐Louis Vincent(Université Libre de Bruxelles), Inder Kaul(Asahi Kasei (United States)), Mradul Kumar Daga(Maulana Azad Medical College), Jawed Fareed(Loyola University Chicago), Chaicharn Pothirat(Chiang Mai University), Kenneth J. Gorelick, Louis M. Guzzi, Jan Pachl(Charles University), Deepak Talwar, M Ramesh(Bangalore Medical College and Research Institute), Jacques Devriendt(Centre Hospitalier Universitaire Brugmann), Marcel Levi(University College London Hospitals NHS Foundation Trust), Seton Henderson(Christchurch Hospital), Naoki Aikawa(Keio University), Gordon R. Bernard(Vanderbilt University Medical Center), Howard Levy(Apple (Israel)), Joe Hirman(Pacific Northwest National Laboratory), Demetrios J. Kutsogiannis(University of Alberta), Joan Vidal Puigserver(Hospital Universitario Son Espases), Eric A. J. Hoste(Ghent University Hospital), Mark Crowther(Population Health Research Institute), Steven P. LaRosa(Eli Lilly (United States)), Charles T. Esmon(Howard Hughes Medical Institute), Yutaka Osawa(Asahi Kasei (United States)), David Ernest(Monash Medical Centre), Joseph E. Parrillo(Hackensack University Medical Center), Daniel U. Blanzaco(National University of General San Martín), Kazuhisa Tsuruta(Asahi Kasei (Japan)), Parthiv Mehta(Ahmedabad Civil Hospital)

Critical Care Medicine

August 27, 2013

Cited by 322

|JAMA|2016|28.1k

|Intensive Care Medicine|1996|11.7k

|Critical Care Medicine|2013|9.7k

|Intensive Care Medicine|2013|7.3k

|Intensive Care Medicine|2017|6.8k

Related Papers